HLA-DQ B1*0201 and A1*0102 Alleles Are Not Responsible for Antituberculosis Drug-Induced Hepatotoxicity Risk in Spanish Population.
OBJECTIVE
To evaluate the role of human leukocyte antigen (HLA) class II DQB1*0201 and DQA1*0102 in the risk of antituberculosis drug (ATD)-induced hepatotoxicity (ATDH) in a cohort of tuberculosis patients of Caucasian origin from Spain.


METHODS
Matched case-control study including active tuberculosis (TB) patients from Spain (Caucasian) treated with first-line ATD (Isoniazid, Rifampin, and Pyrazinamide). Presence or absence of HLA class II DQB1*0201 and DQA1*0102 alleles were compared between cases and controls.


RESULTS
We included 110 TB patients, 55 ATDH cases, and 55 sex-matched controls. The analysis of the presence of HLA-DQB1*0201 and HLA-DQA*0102 did not show significative differences between both groups [presence of HLA-DQB1*0201 53.6% of the cases vs. 45.4% of the controls, OR: 1.63 95% CI (0.62-4.52) p = 0.38; presence of HLA-DQA*0102 7.5% of cases vs. 20% of controls, OR: 0.36 95% CI (0.08-1.23) p = 0.12]. After multivariate logistic regression analysis including in the model, other potential risk factors of hepatotoxicity HLA class II DQB1*0201 and DQA1*0102 alleles were not found significantly associated with the risk of development ATDH. We could not demonstrate an association between HLA-DQA1*0102 and HLA-DQB1*0201 with the risk of ATDH in this Caucasian population of Spanish origin.
NeumoVigol+i Research Group, Pulmonary Department, EOXI Vigo, Biomedical Research Institute Vigo (IBIV), Alvaro Cunqueiro Hospital , Vigo , Spain.
Virginia
V
Leiro-Fernández
Biochemical, Genetics and Immunology Department, Biology Faculty, Vigo University , Vigo , Spain.
Diana
D
Valverde
NeumoVigol+i Research Group, Pulmonary Department, EOXI Vigo, Biomedical Research Institute Vigo (IBIV), Alvaro Cunqueiro Hospital , Vigo , Spain.
Rafael
R
Vázquez-Gallardo
Clinic Analysis Department, EOXI Vigo, Alvaro Cunqueiro Hospital , Vigo , Spain.
Lucía
L
Constenla-Caramés
Preventive Medicine Department, EOXI Vigo, Alvaro Cunqueiro Hospital , Vigo , Spain.
Víctor
V
Del Campo-Pérez
NeumoVigol+i Research Group, Pulmonary Department, EOXI Vigo, Biomedical Research Institute Vigo (IBIV), Alvaro Cunqueiro Hospital , Vigo , Spain.
Alberto
A
Fernández-Villar
DQA1*0102; DQB1*0201; first-line antituberculosis drugs; hepatitis; pharmacogenetics susceptibility